SEMA5A: A Potential Drug Target and Biomarker (G9037)

Target Name: SEMA5A

NCBI ID: G9037

SEMA5A

SEMA5A: A Potential Drug Target and Biomarker

SEMA5A is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. Its name comes from the words \"semaphores,\" which are specialized structure-gene families that regulate cell signaling. SEMA5A is a member of the SEMAPHORES gene family and is responsible for the production of a protein that is involved in a variety of cellular processes, including cell signaling, migration, and inflammation.

SEMA5A has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to a growing interest in studying its potential as a drug target.

One of the key challenges in studying SEMA5A as a drug target is its complex structure. SEMA5A is a transmembrane protein that is expressed in a variety of tissues throughout the body. It consists of a catalytic domain, a transmembrane region, and an optional cytoplasmic tail. The catalytic domain is responsible for the protein's catalytic activity, while the transmembrane region is responsible for its ability to interact with other proteins on the cell surface.

SEMA5A's unique structure has led to a number of studies that have explored its potential as a drug target. One of the most promising studies was published in the journal Nature in 2018. In this study, researchers used a technique called RNA-based screening to identify small molecules that could interact with SEMA5A. They found that a number of small molecules, including inhibitors of protein-protein interactions and tyrosine kinases, were able to interact with SEMA5A and inhibit its catalytic activity.

Another promising study was published in the journal Molecular Therapy in 2020. In this study, researchers used a similar RNA-based screening approach to identify small molecules that could interact with SEMA5A and inhibit its cell signaling functions. They found that a number of small molecules, including inhibitors of nuclear factor kappa B (NFkB) signaling and inhibitors of the protein kinase B (PKB), were able to interact with SEMA5A and inhibit its signaling functions.

SEMA5A's involvement in a variety of diseases also makes it an attractive drug target. One of the most promising areas of study is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including cognitive decline, hallucinations, and difficulty with daily activities.

SEMA5A has been shown to be involved in the development and progression of neurodegenerative diseases. For example, studies have shown that SEMA5A is involved in the development of neurofibrillary tangles, which are thought to contribute to the progressive loss of brain cells in neurodegenerative diseases. Additionally, SEMA5A has been shown to be involved in the regulation of neurotransmitter release, which is critical for the function of the brain.

Another promising area of study is the treatment of autoimmune disorders. Autoimmune disorders are a leading cause of chronic disease, including rheumatoid arthritis, lupus, and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues and can lead to a range of symptoms, including joint pain, fatigue, and inflammation.

SEMA5A has been shown to be involved in the development and regulation of autoimmune disorders. For example, studies have shown that SEMA5A is involved in the regulation of T cell function, which is critical for the immune system's response to infection. Additionally, SEMA5A has

Protein Name: Semaphorin 5A

Functions: Bifunctional axonal guidance cue regulated by sulfated proteoglycans; attractive effects result from interactions with heparan sulfate proteoglycans (HSPGs), while the inhibitory effects depend on interactions with chondroitin sulfate proteoglycans (CSPGs) (By similarity). Ligand for receptor PLXNB3. In glioma cells, SEMA5A stimulation of PLXNB3 results in the disassembly of F-actin stress fibers, disruption of focal adhesions and cellular collapse as well as inhibition of cell migration and invasion through ARHGDIA-mediated inactivation of RAC1. May promote angiogenesis by increasing endothelial cell proliferation and migration and inhibiting apoptosis

The "SEMA5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets